LUPIN

Lupin share price & results

Lupin Limited· Healthcare

Indian pharma major manufacturing generics, complex generics, biosimilars and APIs, sold in 100+ countries.

₹1,950 −1.35%
MCap ₹92.7k Cr Price to earnings (TTM to Sept 2026) 16.46× Return on equity (TTM to Sept 2026) 23.42%

Free account: unlock 50 concall reads/mo, 5 full guidance ledgers, and same-day LUPIN alerts.

Results to: Sept 2026 Latest analysed call: Q2 FY27 Ownership as of: Sept 2026
LUPIN at a glance Plain-English snapshot from filed results & analysed earnings calls

Guidance Track Record

Management guidance vs. actual results

4 of 6 judged targets kept · 18 open · verdicts reflect calls analysed to Q2 FY27.

Lupin Limited management guidance track record on Inve: 24 targets tracked across analysed earnings calls (4 achieved, 2 missed, 18 open).

Watch execution in Operations & Margins (1 achieved · 2 delayed/missed).

TargetOriginal wordingSaidLatest callVerdict
Operations FY26 EBITDA Margin
24% to 25%
Q1 FY26
Q2 FY27:Target period has passed.
Achieved
Operations Effective Tax Rate FY26
around 19%
Q1 FY26
Q2 FY27:Target period has passed.
Missed
Operations Effective Tax Rate FY27
25% - 26%
Q4 FY26
Q2 FY27:Management reaffirmed the revised full-year ETR guidance of around 27%-28%.
Revised Down

Source: Inve Guidance Tracker for Lupin Limited · to Q2 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Lupin Limited's 24 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 21 more targets are in the full ledger.

Get the Inve app for Android on Google Play Get the Inve app for Android on Google Play Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Latest analysed call · Q2 FY27 · 4 Nov 2026

Q2 FY27: Lupin Limited Q2 FY27

Lupin delivered a steady Q2 FY27 with 11% YoY revenue growth to ₹7,827 crores, anchored by solid performance in India (+14.7% YoY) and Other Developed Markets (+46% YoY). However, profitability faced pressure as EBITDA margin dropped to 25.1% from 31.3% last year due to intensifying generic competition in Tolvaptan in the US and higher operating expenses. The company maintained its full-year FY27 guidance of USD 1.1-1.2 billion for US revenue and 24-25% EBITDA margin, supported by upcoming complex generics, 505(b)(2) launches like Apixaban, and biosimilars.

What management highlighted

  • Total revenues from operations grew 11% YoY to ₹7,827 crores from ₹7,048 crores in Q2 FY26
  • India formulation business grew 14.7% YoY, with chronic therapies growing 19.5% in H1 and accounting for 66% of portfolio mix
  • Other Developed Markets (Europe, Canada, Australia) grew 46% YoY to ₹1,182 crores, contributing 15% of total revenues

Source: Inve analysis of Lupin Limited’s Q2 FY27 earnings call · to 4 Nov 2026

Compare across 8 analysed calls

Price & Snapshot

₹1,950 −1.35% · −₹26.7

Last close 17 Nov 2026 · NSE · INR · Source: Inve

Performance −5.1% 1Y

₹2.0k₹2.2k₹2.4kNov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 8 May 2026Q1 FY27 — 7 Aug 2026Q2 FY27 — 4 Nov 2026

1Y: ₹2,055.3 on 14 Nov 2025 → ₹1,950. High ₹2,514.8 (21 Jul 2026), low ₹1,922 (22 Oct 2026).

Previous close
₹1,976.7
Market cap
₹92.7k Cr
52-week range
₹1,922 – ₹2,514.8
One year
−4.98%
Price to earnings (TTM to Sept 2026)
16.46×
Return on equity (TTM to Sept 2026)
23.42%

Reported

Key financial metrics & valuation ratios

Revenue: 3,567 ₹ crore (−12.3% YoY) · Net profit: -5.9 ₹ crore (−100.4% YoY) · Return on equity: 23.42 % (+8.2 pts). Every row keeps its filed period and basis.

MetricValueChangeBasisPeriodNote
Revenue3,567 ₹ crore−12.3% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin5.9 %−23.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit-5.9 ₹ crore−100.4% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity23.42 %+8.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin19.77 %+13.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026
(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)24.23 %+9.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Revenue change against the same period one year earlier.

Source: Quarterly results & TTM/FY financial ratios · to Sept 2026

Business Mix

Where revenue comes from

a) Pharmaceuticals leads at 99.5% of revenue across 3 operating segments (As of 30 Jun 2026).

a) Pharmaceuticals 99.5% · ₹8,234.35 Cr
b) Others 0.5% · ₹43.03 Cr
Less: Inter segment 0.0% · ₹0.00 Cr

Explore full multi-period segment shift & margins →

Customers, suppliers & partners

Customers, suppliers & partner mentions

Named customers, suppliers, and partners mentioned on recent earnings calls. Click any row to read the disclosure.

Counterparties named by Lupin Limited

  • Lupin Limited → partners with → Yuvezzi (Tenpoint Therapeutics)

    Partners with · Announced · Q2 FY27
  • Lupin Limited → acquires or invests in → VISUfarma

    Acquires / invests · Closed / completed · Q2 FY27
  • Lupin Limited → acquires or invests in → VISUfarma

    Acquires / invests · Closed / completed · Q1 FY27
  • Lupin Limited → acquires or invests in → VISUfarma

    Acquires / invests · Closed / completed · Q4 FY26
  • Lupin Limited → acquires or invests in → VISUfarma

    Acquires / invests · Announced · Q3 FY26
  • Lupin Limited → acquires or invests in → VISUfarma

    Acquires / invests · Announced · Q2 FY26
  • Lupin Limited → acquires or invests in → Xopenex®

    Acquires / invests · Closed / completed · Q4 FY25
  • Lupin Limited → acquires or invests in → Southern Cross

    Acquires / invests · Closed / completed · Q4 FY25
  • Lupin Limited → acquires or invests in → Medisol

    Acquires / invests · Closed / completed · Q4 FY25
  • Lupin Limited → acquires or invests in → Lilly's insulin brand

    Acquires / invests · Closed / completed · Q4 FY25

Similar pressures reported by peers

Tailwind coverage is not available yet.
  • Responses submitted and remediation ongoing following regulatory inspections

    53 other companies · Regulatory policy · Q2 FY27
  • EBITDA margins expected to moderate in H2 FY27 due to pricing pressure in the US, upfront…

    28 other companies · Raw material cost · Q2 FY27
  • Two generic competitors entered Tolvaptan with more expected, causing substantial price…

    9 other companies · Pricing discipline · Q2 FY27

Mentions over time

Q4 2024 – Q3 2026

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Company Reference

Symbol
NSE:LUPIN
Exchange
NSE
Currency
INR

What Lupin Limited does

Sourced to annual report & earnings calls.

Lupin Limited, founded in 1968 by Dr. Desh Bandhu Gupta and headquartered in Mumbai, develops, manufactures and markets generic and complex-generic drugs, biosimilars, specialty medicines and active pharmaceutical ingredients (APIs). It runs manufacturing sites and research centers worldwide, files product approvals with regulators including the US FDA, and sells its portfolio across India, North America, Europe, Latin America, Africa and other emerging markets. It earns revenue by selling branded and generic formulations to hospitals, pharmacies and distributors, and by supplying APIs to external customers as well as its own formulations business. Beyond formulations, it has diversified into adjacent healthcare services including diagnostics (Lupin Diagnostics), digital therapeutics (Lupin Digital Health), neuro-rehabilitation (Atharv Ability), consumer healthcare (LupinLife) and contract development/manufacturing (Lupin Manufacturing Solutions).

Segments

  • India
  • North America (United States)
  • Other Developed Markets
  • Emerging Markets
  • API
Manufacturing sites
15
Research centers
7
Employees ("Lupinites")
24,000+
Countries where products are sold
100+
ANDAs and NDAs filed with US FDA
430
US DMF filings
94
Founded 1968Headquarters Mumbai, India Company website

How the price took the results

Moved an average of ±1.3% across the last 4 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q2 FY274 Nov 263,567 -6−12.3%₹2,015.9 → ₹2,008.6−0.4%
Q1 FY277 Aug 267,172 2,715+25.6%₹2,385 → ₹2,363.5−0.9%
Q4 FY268 May 265,235 2,164+16.7%₹2,460.1 → ₹2,379.5−3.3%
Q3 FY2613 Feb 264,501 717+7.0%₹2,211.1 → ₹2,199.3−0.5%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case & results alerts for Lupin Limited

Free account: one Inve Case, 50 concall reads/mo, 5 full ledgers, and results-day alerts.

Write why you follow Lupin Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance, and notifies you when a new call moves your thesis.

Keep reading

Other Healthcare companies

PEER COMPARISON
Median ₹92,695 Cr Mkt Cap
₹0 Cr₹50,000 Cr₹1.0L Cr₹1.5L CrLupin Limited (LUPIN): ₹92,695 Cr₹92,695 CrLUPINCipla Limited (CIPLA): ₹1.1L Cr₹1.1L CrCIPLAAurobindo Pharma Limited (AUROPHARMA): ₹1.1L Cr₹1.1L CrAUROPHARMAMankind Pharma Limited (MANKIND): ₹1.0L Cr₹1.0L CrMANKINDMANIPALHOS (MANIPALHOS): ₹92,734 Cr₹92,734 CrMANIPALHOSMax Healthcare Institute Limited (MAXHEALTH): ₹89,161 Cr₹89,161 CrMAXHEALTHGlenmark Pharmaceuticals Limited (GLENMARK): ₹73,895 Cr₹73,895 CrGLENMARKAster DM Healthcare Limited (ASTERDM): ₹62,957 Cr₹62,957 CrASTERDMAlkem Lab (ALKEM): ₹61,935 Cr₹61,935 CrALKEM

All Healthcare companies → · Healthcare earnings growth →

Quick Answers

Frequently asked questions on Lupin Limited

Compiled directly from LUPIN's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Lupin Limited (LUPIN) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Lupin Limited reported revenue of ₹3.6k Cr, net profit of ₹-6 Cr, an operating margin of 5.9%. Diluted earnings per share stood at ₹-0.13.

How is Lupin Limited (LUPIN) valued today, and what growth does the stock price imply?

Lupin Limited (LUPIN) trades at ₹1,950, with a market capitalization of ₹92.7k Cr, a trailing P/E multiple of 16.46×, return on equity (ROE) of 28.68%, ROCE of 29.93%.

Did Lupin Limited (LUPIN) management keep or miss its earnings call guidance?

Across 24 management guidance targets tracked from Lupin Limited's earnings calls, 4 were achieved, 2 missed, and 18 remain open (67% delivered among resolved targets). Sampled guidance includes FY26 EBITDA Margin: "24% to 25%" (stated in Q1 FY26, current status: achieved).

Who owns Lupin Limited (LUPIN) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 46.8%, FIIs hold 23.3%, DIIs hold 23.8%, Public shareholders hold 6.1%.

What did Lupin Limited (LUPIN) management cover on its latest concall (Q2 FY27)?

On its Q2 FY27 (Nov 2026) concall, Lupin delivered a steady Q2 FY27 with 11% YoY revenue growth to ₹7,827 crores, anchored by solid performance in India (+14.7% YoY) and Other Developed Markets (+46% YoY). However, profitability faced pressure as EBITDA margin dropped to 25.1% from 31.3% last year due to intensifying generic competition in Tolvaptan in the US and higher operating expenses. The company maintained its full-year FY27 guidance of USD 1.1-1.2 billion for US revenue and 24-25% EBITDA margin, supported by upcoming complex generics, 505(b)(2) launches like Apixaban, and biosimilars. Read Lupin Limited Q2 FY27 concall summary →